Bredesen, ReCODE, and the Naming of Practitioner-Delivered Preventive Regimens

Executive summary

The closest precedent does use a two-level naming architecture—but not the clean “clinical name plus patient brand” system assumed. It evolved into an overlapping, commercially controlled family of eponymous, outcome-claiming, diagnostic, nutritional, training, and facility names.

The most consequential distinction is real: PreCODE is positioned for people without current cognitive impairment who want prevention or risk reduction; ReCODE is positioned for subjective cognitive impairment, mild cognitive impairment, or early dementia and promises reversal. Independent trained practitioners explicitly translate the names as “Prevent Cognitive Decline” and “Reverse Cognitive Decline,” and keep them separate through eligibility, testing intensity, report type, subscription, and clinical workload. 1

Several working assumptions require correction:

• “The Bredesen Protocol” was not merely an organic eponym. Metabolic Programmatics filed to register BREDESEN PROTOCOL in 2018, claiming commercial use since 2016. The application was abandoned in 2019 for failure to respond to an Office action. 2
• ReCODE was deliberate commercial branding. RECODE and RECODE REPORT obtained federal registrations; Apollo operator AHNP, LLC also pursued RECODE PROTOCOL, PRECODE REPORT, and PRECODE PROTOCOL. 3
• The protected asset is not the underlying regimen. The registrations cover medical consultation, assessment, reports, education, and practitioner training—the service system wrapped around generic interventions. 4
• No public FTC, FDA-warning-letter, state-attorney-general, class-action, or advertising-self-regulatory action directly involving Apollo/ReCODE was identified. That does not validate the claims. Current marketing says “Clinically Proven to Reverse Cognitive Decline,” “The ONLY Option Proven,” and “Heal from diabetes,” while the first controlled trial remained a non-peer-reviewed preprint as of August 3, 2026. 5
• Scientific criticism has centered on evidence design and commercialization, not the mere existence of two names. The architecture’s problem is that the consumer names themselves encode the disputed outcomes—prevention and reversal.

The precedent therefore demonstrates that two names can segment markets and support a practitioner network. It also demonstrates how quickly the brand, founder, evidence claims, training economics, and clinical legitimacy can become inseparable.

Naming architecture

The prevention–treatment split

The system’s clearest strategic choice is not “Bredesen Protocol versus ReCODE.” It is PreCODE versus ReCODE.

PreCODE addresses people who are cognitively normal or not yet experiencing recognized impairment but have age, family-history, genetic, metabolic, or other risk concerns. ReCODE addresses people already reporting or demonstrating decline. Trained providers describe PreCODE as “strictly preventative,” lighter and less intensive, while ReCODE is a treatment-oriented program for subjective cognitive impairment, mild cognitive impairment, and early Alzheimer-type dementia. 6

The separation is maintained in practice through:

7

This is commercially elegant: one platform can acquire people before disease, retain them if risk rises, and move them into a more intensive pathway if symptoms emerge. It is also claims-sensitive. The distinction is not expressed through neutral stage labels; the names themselves carry the disputed outcomes prevent and reverse.

Core and adjacent names

The table below covers the materially relevant names identified in the clinical, commercial, diagnostic, training, nutrition, and publishing system. “Origin” is limited to what can be documented; where the individual who coined a term could not be established, that is stated rather than inferred.

Sources for the architecture include the original MEND paper, federal trademark records, current Apollo program and training materials, practitioner explanations, and current Apollo product navigation. 8

What is documented versus inferred

Documented: MEND was the original published scientific label; ReCODE and ReCODE Report were deliberately pursued as source-identifying commercial marks; the company attempted to appropriate the eponymous BREDESEN PROTOCOL for practitioner training; and PreCODE was deliberately constructed as the prevention counterpart to ReCODE. 9

Not established: who personally coined “ReCODE,” whether Bredesen initially encouraged or merely accepted “Bredesen Protocol,” and whether “PreCODE” was first proposed by Bredesen, a company executive, a marketing agency, counsel, or a practitioner. The trademark applicant establishes commercial ownership activity, not individual authorship.

Analysis: the architecture was evolutionary rather than designed in one sitting. It moved from a scientific initialism, to an eponym, to a proprietary diagnostic/report brand, to separate prevention and treatment programs, and then to nutrition, testing, coaching, residential-care, and book extensions. That history matters because copying the visible architecture today would copy the end state—not the conditions under which it emerged.

Correction of the scale assumption

The trade book, trained-practitioner network, proprietary reports, subscriptions, labs, and program content clearly function as the principal commercialization channels visible to the public. Apollo currently sells ReCODE directly as a subscription, integrates Quest laboratory testing, provides educational content and assessments, and connects users with trained practitioners and coaches. 10

What cannot be established from public information is the causal assertion that the book was the primary driver of scale, as opposed to speaking, podcasts, functional-medicine networks, direct response marketing, practitioner referrals, or online communities. Establishing channel contribution would require Apollo’s historical acquisition, attribution, practitioner, subscriber, and revenue data.

Intellectual-property findings

Federal trademark record

11

The PRECODE application statuses should not be treated as current merely because third-party databases show a 2021 extension event. A definitive August 2026 answer requires a current TSDR status export, including any later statement-of-use, abandonment, revival, assignment, or replacement filing. No registration number appeared in the records located during this review.

The eponym was pursued—and failed procedurally

The belief that “Bredesen Protocol” was never registered because it was only an informal name is incorrect.

Metabolic Programmatics filed BREDESEN PROTOCOL as a standard-character mark on April 17, 2018. It claimed first use and first use in commerce on April 30, 2016 and identified the service as healthcare-provider training in evaluating and reversing cognitive decline. The record shows a non-final Office action in August 2018 and abandonment on March 10, 2019 for failure to respond or late response. 2

The accessible record establishes the procedural ground for abandonment, but not the examiner’s complete substantive objections. The Office-action document itself would be needed to determine whether the examiner raised surname/eponym consent, descriptiveness, likelihood of confusion, specimen, identification-of-services, or another issue. It would be inaccurate to say the USPTO refused the mark because eponymous protocol names are inherently unregistrable.

The abandonment had an important practical consequence: the eponym remained widely usable as a referential description of Bredesen’s approach, while the company concentrated enforceable federal rights in RECODE and RECODE REPORT.

What the registrations actually protect

The registrations do not give Apollo ownership of generic drugs, supplements, dietary practices, exercise, sleep optimization, laboratory biomarkers, or the abstract idea of a personalized multifactorial dementia regimen.

They protect source-identifying use of the marks in defined service categories, especially:

• medical consultation and assessment;
• provider education and training;
• branded reports and associated delivery;
• potentially related software, content, and platform elements under copyright, contract, trade-secret, or additional trademark rights.

RECODE REPORT’s registration expressly disclaims exclusive rights in “REPORT” apart from the mark as a whole. The PRECODE applications similarly disclaim “REPORT” or “PROTOCOL.” 4

This is the central IP lesson for a generic-component regimen: the ownable layer is the source-identifying service system, not the medical ingredients. The commercial moat can reside in the algorithm, data structure, report, training, manuals, certification criteria, software, community, contracts, quality controls, and brand goodwill even when clinicians remain legally able to prescribe the same generic components independently.

Enforcement behavior

AHNP has used TTAB proceedings to police the RECODE family against marks including ADRENAL RECODE, another RECODE application, and THE RECODE. The TTAB record identifies RECODE, RECODE REPORT, and the RECODE PROTOCOL application as asserted properties. 12

That behavior shows that the name was treated as a scalable platform asset rather than merely a label for a published clinical method. It also exposes a cost of choosing a common English word: “recode” is attractive across health, coaching, genetics, software, and behavior-change businesses, increasing opposition and policing burdens.

International filings

RECODE REPORT was used as the basis for Madrid International Registration 1,522,998, dated February 20, 2020. PRECODE REPORT was used for Madrid International Registration 1,522,040, also dated February 20, 2020. A Canadian official record located for PRECODE REPORT identifies Canadian application/registration number 2,019,677, AHNP, LLC, priority from U.S. serial 88585259, and Class 44 medical-assessment and consultation services. 13

A Madrid international registration is a filing mechanism, not proof that every designated country ultimately granted and continues to maintain protection. A complete jurisdiction-by-jurisdiction status schedule would require WIPO Madrid Monitor and each designated national office.

Regulatory, claims, physician, and scientific reception

No identified direct enforcement—but aggressive current claims

No public enforcement matter was identified through searches of FTC warning letters and cases, FDA warning letters, state-attorney-general materials, reported class actions, or national advertising self-regulatory decisions that directly named Apollo Health, AHNP, ReCODE, PreCODE, or the Bredesen Protocol.

This is a bounded negative finding, not proof of regulatory clearance. FDA notes that warning-letter collections are not necessarily exhaustive and directs requesters to FOIA for additional records; FTC similarly describes warning letters as one of several enforcement tools. 14

Because no direct agency or court action was located, there is no regulator-identified phrase to quote as an adjudicated or formally challenged Bredesen claim.

There is, however, unusually strong current marketing language:

“Clinically Proven to Reverse Cognitive Decline”

“The ONLY Option Proven to Reverse Cognitive Decline”

“Reverse cognitive decline”

“Regain your quality of life & restore independence”

“Heal from diabetes & other chronic conditions”

These statements appear on Apollo’s current ReCODE sales page. The page also states that 84% of participants improved in its prior clinical trial. 15

The evidence status creates tension with “clinically proven.” The 2022 published study was a 25-person, single-arm proof-of-concept trial. Twenty-one of 25 study partners rated participants as improved, but there was no randomized control group. 16

Apollo describes a later 2025 study as a randomized, multicenter controlled trial and reports statistically significant cognitive gains. As of August 3, 2026, Apollo’s own page stated that peer-reviewed publication was “in progress”; the publicly located manuscript was a preprint reporting 50 precision-medicine participants and 23 standard-of-care controls. 17

The claim issue is therefore not that no clinical research exists. It is that the marketing language compresses a contested evidentiary progression—case reports, a small uncontrolled trial, and a not-yet-peer-reviewed controlled trial—into the categorical phrase “proven.”

Did “ReCODE” itself create legal exposure?

No evidence was found that an agency challenged the mark because it can be read as Reverse Cognitive Decline.

Nevertheless, the naming and copy cannot be cleanly separated. Providers explicitly teach the public that ReCODE means reversal of cognitive decline and PreCODE means prevention of cognitive decline. 18

A neutral arbitrary mark can acquire risky claims in advertising, but the advertiser can revise those claims while retaining the name. An outcome-encoded name is harder to rehabilitate: every use repeats the implied endpoint. That creates three potential consequences:

• Substantiation burden: the name may contribute to the overall net impression that reversal or prevention is the expected program result.
• Durability risk: if future studies support slowing but not reversal, the commercial identity becomes scientifically misaligned.
• Practitioner amplification: licensed or trained clinicians can expand the implied promise when explaining the acronym to patients.

Those are legal-risk analyses, not findings that Apollo violated the law. No adjudication located in this research establishes that RECODE or PRECODE is inherently deceptive.

Evolution of the evidence

The positive evidence has advanced, but the naming and commercialization advanced faster.

19

This chronology disconfirms the strongest version of the criticism that the program has “only anecdotes.” It also confirms the more precise criticism: for most of the period in which the brand claimed prevention and reversal, the public evidence was uncontrolled. Even in 2026, the controlled evidence located remained a preprint.

Named academic criticism

Joanna Hellmuth and colleagues’ peer-reviewed critique, “Can we trust The End of Alzheimer’s?,” separated several problems:

Evidence criticism: the early reports lacked control groups, prespecified endpoints and complete systematic reporting; patients received numerous simultaneous interventions; and the design did not permit attribution of improvement to the protocol rather than bias, practice effects, natural variability, or selected reporting.

Commercialization criticism: patients could be directed toward subscriptions, proprietary reports and trained practitioners before conventional efficacy evidence was available, creating financial and conflict-of-interest concerns.

Patient-risk criticism: a burdensome regimen can impose substantial laboratory, supplement, practitioner, dietary and opportunity costs, and may divert patients from evidence-based care or appropriate clinical trials. 20

A separate ethics analysis described commercialization of the “Bredesen-approved” protocol, report and practitioner ecosystem as an example of innovation reaching vulnerable patients before adequate controlled evidence, emphasizing cost, therapeutic misconception, conflicts of interest and the difficulty of informed consent where testimonials and reversal claims dominate. 21

Later methodological commentary argued that personalized systems-biology trials can be valuable but should not use complexity as a reason to relax basic controls, transparent endpoints, registration and replicability. 22

Apollo’s response is that Alzheimer’s is multifactorial, conventional monotherapy trial designs are poorly suited to personalized combinations, the disease is fatal and progressive, and waiting for large traditional trials would deny patients access to a promising low-risk strategy. Apollo also points to the progression from cases to prospective and controlled research. 23

Both directions matter. The critics were correct that uncontrolled reports could not prove reversal. Apollo was also correct that a personalized combination can be studied prospectively and, eventually, in a controlled design. The unresolved question is not whether complex regimens can be tested; it is what level of evidence justifies categorical prevention and reversal claims.

Was the name itself criticized by physicians?

No peer-reviewed critic located argued that an eponymous name, by itself, invalidated the approach. The dominant objections concerned study design, conflicts, costs, biological assumptions, claim strength and premature commercialization.

The eponym’s effects appear indirect:

• Potential credibility benefit: “Bredesen Protocol” ties the regimen to a credentialed neurologist and laboratory investigator rather than to an anonymous wellness brand.
• Potential credibility cost: specialists may read a living-founder eponym attached to a proprietary network as authority marketing, particularly when much of the supporting literature is founder-authored.
• Searchability benefit: the eponym gives physicians and patients a stable referent across books, papers, podcasts and provider sites.
• Evidence contamination: criticism of one paper, commercial claim or founder statement can attach to the entire protocol family.

The evidence does not show that the eponym persuaded skeptical academic neurologists. Nor does it show that removing it would have resolved their objections. Naming appears secondary to evidence quality—but it magnified the reputational consequences of that evidence.

Practitioner network mechanics and failure modes

How the network operates

Apollo’s current practitioner training contains more than 36 hours of instruction, at least ten modules and multiple instructors. The curriculum covers the history of the protocol, interpretation of contributors and reports, implementation, and integration with Apollo’s platform. Coach training similarly contains more than 36 hours and includes scope-of-practice material. 24

Within the platform:

• patients enroll as ReCODE or PreCODE clients;
• practitioners may onboard clients or arrange payment for their subscriptions;
• laboratory and clinical information feed a proprietary algorithm;
• a ReCODE or PreCODE report supplies priorities and recommended actions;
• clinicians retain responsibility for medical assessment, prescribing and individualization;
• coaches support behavior change but are trained to remain within a non-prescribing scope. 25

Apollo currently markets ReCODE at $75 per month or $810 annually, with a 12-month commitment. Quest testing is listed at $855 initially, $224 at six months, and different repeat-year pricing; practitioner visits, supplements, prescriptions and additional testing are separate. 15

Individual clinics layer their own packages onto the platform. One publicly visible practitioner example offered a six-month PreCODE package for $1,200, with physician and coaching visits, while excluding labs, medicines and supplements. Such figures are examples, not standardized network pricing. 26

A current public price for clinician certification was not established. The training page describes the curriculum but does not expose a complete purchase price without account or enrollment flow. Historical prices reported by critics or practitioners may no longer be current.

What practitioners are licensed or permitted to say

The public materials establish approved program names, education, referral status and use of Apollo’s reports. They do not disclose the complete practitioner trademark license, certification agreement, claims manual, audit provisions, termination rights, mandatory disclaimers or permitted-claims matrix.

That prevents a definitive answer to whether practitioners are:

• required to use “ReCODE Protocol” rather than “Bredesen Protocol”;
• permitted to say “reverse Alzheimer’s”;
• prohibited from saying “cure”;
• obligated to distinguish Apollo’s platform from their independent medical practice;
• audited for website or social-media claims;
• required to use particular disclaimers or evidence citations.

A 2026 residential affiliate’s publication guidance is revealing but not controlling. It instructs writers to avoid “Guaranteed reversal,” “Alzheimer’s cure,” “Guaranteed improvement,” and “FDA-approved ReCODE treatment,” while using softer phrases such as “cognitive support” and “outcomes vary.” 27

That suggests downstream partners recognize claims risk. It does not prove those rules came from Apollo or apply network-wide.

Founder and governance dependency

Apollo states that its proprietary algorithm was created and is regularly updated by Bredesen, and he remains publicly central as Chief Science Officer, research authority, author and recurring educational figure. 28

No public succession plan, independent clinical-governance charter, algorithm change-control board, evidence-review committee or post-Bredesen brand-transition arrangement was identified.

The architecture therefore contains four kinds of key-person dependency:

Where the architecture created problems

Brand and evidence became entangled. The company’s treatment brand means “reverse cognitive decline,” while the prevention counterpart means “prevent cognitive decline.” A negative or equivocal trial would not merely weaken a marketing claim; it would challenge the semantic premise of the brands.

Commercial scale preceded conventional validation. Books, subscriptions, reports and practitioner training created a functioning market while the evidence consisted largely of case reports. That sequencing became a central part of the academic critique. 29

The eponym did not stay informal. Attempting to register BREDESEN PROTOCOL blurred the line between a scientific method named after its investigator and a proprietary provider-training asset. The failed registration left a fragmented result: the public could keep using the eponym while Apollo controlled the ReCODE layer. 2

Prevention and treatment became commercially separable before they were evidentially separable. Preventing decline in asymptomatic people requires longer follow-up, larger samples and different endpoints than improving test scores in symptomatic patients. The brand architecture offers a confident prevention pathway even though the identified trials primarily concerned MCI and early dementia, not incident-dementia prevention in cognitively normal populations. 30

Practitioner variability is structurally unavoidable. A personalized protocol involving diet, sleep, exercise, supplements, laboratory interpretation, infection or toxin workups, hormones and prescriptions gives clinicians substantial discretion. Certification can establish a common language but cannot make every implementation equivalent.

Outcome attribution is weak. If a patient improves, neither clinician nor researcher can readily identify the active component. If a patient deteriorates or suffers harm, the branded “protocol” may be blamed even when an individual practitioner added nonstandard interventions.

Reimbursement remains fragmented. Unlike CMS-approved intensive cardiac-rehabilitation programs, ReCODE’s visible business model relies primarily on direct subscriptions, cash-pay clinicians, laboratories and supplements. The generic nature of components does not make the integrated service reimbursable as a unit.

Trademark sprawl increases governance demands. ReCODE, ReCODE Report, ReCODE Protocol, PreCODE, PreCODE Report, PreCODE Protocol, ReCODE+, KetoFLEX, Cognoscopy, Cq and related names require consistent definitions and evidence boundaries. Without rigorous architecture management, each extension can make different implied claims.

Affiliated supplements intensify conflict concerns. Apollo’s ecosystem links to branded supplement offerings while supplement sellers disclaim diagnosis, treatment and FDA evaluation. The legal separation does not necessarily prevent patients from perceiving the supplements as part of a clinically validated branded treatment. 31

Comparator cases

The comparators show that there is no single successful naming model. Eponyms, descriptive clinical labels, consumer brands and reimbursement-recognized program names can all work—but they produce different legitimacy, control and claims consequences.

Comparison table

Wahls Protocol

The Wahls system uses the same name across the trade book, diet, patient community and professional education. It is more structurally economical than Bredesen/ReCODE: there is no widely recognized separate neutral clinical term underneath a consumer program.

Randomized and controlled dietary studies have reported clinically meaningful within-group improvements in fatigue and quality of life, while later analyses continue to characterize evidence on disability and disease progression as preliminary or sparse. 32

What helped: the eponym provides one memorable search term, makes founder authority legible and avoids translation between clinical and consumer names.

What hurt: founder, diet, evidence and commercial education are inseparable. “The Wahls Protocol” can mean a book, a diet variant, a research intervention or whatever an individual follower implements, complicating reproducibility.

Ornish

CMS formally approved Dr. Ornish’s Program for Reversing Heart Disease as a covered intensive cardiac-rehabilitation program under Medicare Part B in 2010 after evaluating whether the published evidence and program structure met statutory requirements. 33

The architecture combines an eponym, an explicit outcome claim and a standardized institutional-delivery system. Unlike ReCODE, the branded program has an unusual payer-recognized identity: coverage follows qualifying patients receiving the defined program through eligible providers, not simply any physician’s use of similar lifestyle advice.

What helped: standardization, published longitudinal evidence, institutional implementation and a formal CMS determination converted a brand into a reimbursable service category.

What hurt: organizations offering substantively similar interventions cannot automatically rely on Ornish’s approval; affiliation and program fidelity matter. The brand becomes both the evidence container and the reimbursement gate.

Pritikin

CMS approved the Pritikin Program for intensive cardiac rehabilitation effective August 12, 2010. CMS expressly observed that the program itself was not subject to FDA oversight, illustrating that a multi-component behavioral program can obtain Medicare coverage without being an FDA-regulated drug product. 34

What helped: one eponymous master brand spans residential experience, diet philosophy and reimbursable clinical program.

What hurt: the same name covers several different experiences, and CMS coverage is limited to the defined ICR context. Consumer familiarity does not itself confer clinical equivalence or reimbursement.

Shoemaker Protocol and CIRS

The Shoemaker system is highly relevant structurally. It combines the clinical acronym CIRS—Chronic Inflammatory Response Syndrome—with the Shoemaker Protocol, a staged treatment framework involving environmental evaluation, specialized laboratory interpretation and off-label prescription drugs such as cholestyramine. The commercial site maintains a certified-practitioner directory and describes a multistage examination process including screening, written and oral components. 35

This architecture effectively assigns different jobs to two names:

• CIRS names the asserted condition and provides clinical-sounding legitimacy.
• Shoemaker Protocol identifies the founder-controlled treatment and certification lineage.

What helped: clinicians can discuss CIRS as a condition while differentiating certified protocol delivery; the eponym supports training control.

What hurt: the condition’s scientific acceptance and the founder’s treatment model remain tightly linked in public understanding. A practitioner may appear to validate the diagnosis merely by offering the branded protocol. A 2024 review favorable to CIRS reported that the Shoemaker Protocol dominated the available treatment literature, which also signals limited independence of the evidence base. 36

Coimbra Protocol

The Coimbra Protocol uses individualized, extremely high-dose vitamin D for autoimmune disease, particularly multiple sclerosis, with laboratory-guided dosing, dietary restrictions and medical monitoring. Publications and practitioner networks refer to it by the originator’s name, but no comparable global consumer platform brand governs patient access. A German training organization states that Cicero Coimbra trained more than 150 physicians, historically without charging for the training. 37

Published reports address safety and propose a vitamin-D-resistance hypothesis, but independent MS organizations state that efficacy is not corroborated by adequate published evidence and warn of potentially serious complications from very high vitamin D dosing. 38

What helped: one clinically descriptive eponym travels across borders without requiring a central subscription or consumer master brand.

What hurt: weak centralized control means variable implementation, uncertain credentialing, inconsistent claims and limited capacity to police quality. This is the clearest counterexample to the proposition that a separate patient brand is necessary.

Gonzalez Regimen

The Gonzalez regimen combined individualized diets, extensive supplements, pancreatic enzymes and detoxification procedures for cancer. Its name was both the clinical shorthand and patient-facing identity.

The strongest comparative evidence was damaging. NCI reports that patients with inoperable pancreatic cancer receiving standard chemotherapy had median survival of approximately 14 months, versus 4.3 months for the Gonzalez regimen; chemotherapy patients also reported better quality of life. Gonzalez disputed aspects of trial execution, including adherence. 39

What helped initially: the founder eponym consolidated a complicated regimen into an understandable package and supported a high-touch practice.

What went wrong: the name made the comparative failure inseparable from the founder and method. There was no neutral platform identity, independent governance or successor evidence base capable of absorbing the result. It is the strongest disconfirming case for assuming that personalization or complexity can compensate for controlled outcomes.

Comparator synthesis

The successful comparators did not succeed because they had one name or two.

They succeeded where four conditions aligned:

• the intervention was sufficiently standardized to be evaluated;
• the claim embedded in the name was supported closely enough by accepted evidence;
• the delivery organization controlled fidelity;
• an external institution—especially CMS—recognized the program rather than merely its founder’s authority.

The failed or controversial comparators show the inverse: an eponym or brand can accelerate adoption, but it cannot compensate for weak comparative evidence, decentralized quality, excessive claims or founder dependency.

Clinical naming conventions

Component initialisms are normal clinical infrastructure

Mainstream medicine routinely uses component-derived initialisms as non-consumer clinical shorthand.

FOLFOX abbreviates folinic acid/leucovorin, fluorouracil and oxaliplatin. Variants such as FOLFOX-4, FOLFOX-6 and modified FOLFOX-6 distinguish doses and schedules. 40

R-CHOP abbreviates rituximab, cyclophosphamide, doxorubicin/hydroxydaunorubicin, vincristine/Oncovin and prednisone. Some letters derive from historical or brand-associated drug names rather than modern generic names. 41

Other oncology examples include MOPP, FLOT, FOLFIRI, CAPOX and R-EPOCH. NCI dictionaries and treatment summaries use these names as ordinary clinical terms. 42

In infectious disease, WHO uses BPaL for bedaquiline, pretomanid and linezolid, and BPaLM when moxifloxacin is added. 43

NIH HIV guidance uses slash-form component shorthand such as BIC/FTC/TAF for bictegravir/emtricitabine/tenofovir alafenamide. 44

Who assigns the initialisms?

There is generally no universal naming authority comparable to the body that assigns generic drug names.

A regimen shorthand typically originates with investigators, cooperative trial groups, guideline authors, manufacturers of a fixed-dose product, or clinical communities. It becomes standard through repeated use in protocols, journal articles, labels, dictionaries and guidelines. NCI, NIH, WHO and professional societies then normalize it by using and defining it.

This creates a practical governance system without necessarily creating ownership.

Are regimen initialisms ownable?

A purely component-descriptive or generic regimen name is difficult to monopolize for the regimen itself. USPTO guidance states that generic terms cannot function as federally registrable trademarks and that merely descriptive terms may be refused when they immediately describe an ingredient, characteristic, function, purpose or use. 45

Protectability can differ by context. An initialism that is descriptive for a treatment combination might still function as a mark for unrelated software, education or administrative services, or may acquire limited source significance in a particular field. Registration also does not prevent fair clinical or referential use.

The practical norm is that clinicians, journals and guidelines can use FOLFOX or R-CHOP without obtaining a brand license.

Clinical shorthand and consumer brands can coexist

The cleanest example is HIV treatment:

• BIC/FTC/TAF is the component-level clinical shorthand.
• Biktarvy is the proprietary brand of the fixed-dose tablet containing those agents.

NIH displays the two side by side as generic abbreviation and trade name. 46

R-CHOP likewise includes rituximab, which has been sold as Rituxan and other brands, and vincristine, whose “O” historically references Oncovin. The regimen shorthand remains clinically usable regardless of which eligible branded or generic components are procured.

This establishes that a neutral clinical shorthand can sit underneath or alongside a proprietary program identity without conceptual conflict. The two layers serve different functions:

The coexistence works best when the clinical shorthand accurately specifies what was studied and the brand identifies who delivered it. It works poorly when the brand claims a clinical outcome broader than the evidence attached to the underlying regimen.

The case against borrowing the structure and unresolved questions

The strongest case against two names

A two-name architecture may be the wrong choice for an evidence-led preventive regimen for nine reasons.

It creates legitimacy arbitrage. A formal clinical name can lend scientific gravity to a patient program before the patient program itself has been independently validated. The company can cite literature under the clinical label while selling a broader, evolving implementation under the brand. Patients and practitioners may not notice the difference.

It fragments the evidence record. Trials, case reports, adverse events, conference presentations and real-world data may appear under different names. This complicates literature searches, systematic reviews, informed consent and post-market learning. Bredesen’s intervention has appeared as MEND, the Bredesen Protocol, ReCODE, a precision-medicine approach and related branded reports.

It invites silent scope expansion. A narrowly specified clinical regimen can become a broad patient program incorporating diagnostics, diet, coaching, additional supplements, proprietary algorithms and future interventions. The commercial brand may remain constant even as the actual regimen changes.

It can conceal non-equivalence. A physician may say that a patient is “on the protocol” while modifying doses, supplements, testing, eligibility and follow-up. A separate umbrella brand makes heterogeneous implementations look like one validated product.

It weakens the academically credentialed inventor’s strongest asset: falsifiability. An evidence-first investigator benefits when the thing sold is recognizably the thing tested. Two names increase the opportunity for post hoc arguments that a negative study tested the clinical regimen but not the “full program,” or that a successful study validates commercial extensions not actually included.

The prevention/treatment split can hardcode claims before natural-history evidence exists. A prevention brand implies fewer future cases, slower biomarker progression or delayed onset. Demonstrating those outcomes ordinarily requires longer and larger studies than demonstrating short-term target engagement. Bredesen’s PreCODE architecture commercially asserts a prevention category while the identified clinical trials were centered on symptomatic MCI and early dementia. 30

A second name doubles claims governance rather than reducing it. Every website, practitioner page, referral directory, podcast, training deck and patient testimonial must correctly distinguish the names. The risk is not just confusion; it is that practitioners will use the more dramatic consumer interpretation to acquire patients.

It increases IP and operating expense without creating clinical exclusivity. Two brands require separate clearance, filings, specimens, renewals, domains, monitoring, licensing and enforcement. None prevents an unaffiliated physician from prescribing generic components or describing a similar regimen in non-infringing terms.

It gives critics two targets and a bridge between them. The eponym ties every failure to the inventor; the consumer brand ties every commercial claim to the company. Because the public knows they are the same system, reputational separation is mostly illusory.

The Bredesen precedent does not demonstrate that two names produce physician legitimacy. It demonstrates that a clinical/eponymous identity and a consumer program can become so tightly associated that criticism of either reaches both.

Disconfirming considerations in favor of two layers

The countercase should not be ignored.

A separate clinical shorthand can improve precise prescribing, publication, trial registration and discussion of mechanism. A separate program mark can identify trained delivery, software, quality controls, patient education and community services that are genuinely not part of the molecular regimen. Oncology and HIV demonstrate that component shorthand and a proprietary identity can coexist. 47

The distinction is defensible when:

• the clinical term is stable, descriptive and freely usable;
• the program brand does not encode an unproven endpoint;
• publications state exactly which version and components were tested;
• program extensions cannot claim the clinical evidence automatically;
• licensing contracts impose meaningful claims and quality controls;
• adverse events and outcomes remain traceable across both names.

The Bredesen system only partially meets those conditions. Its PreCODE/ReCODE segmentation is operationally understandable, but the brands encode the very efficacy propositions under dispute.

Open questions and what would resolve them

The core decision uncertainty is not whether Bredesen built a two-name system. He did—and then expanded it into many names. The unresolved question is whether the segmentation value of that architecture exceeds the scientific, regulatory, governance and reputational cost of maintaining two identities for what patients and physicians will inevitably understand as one intervention.

Sources

Numbered markers in the text above link to the 47 sources below. Every entry is the source as recorded in the research file; none were added, inferred, or edited.

1. 1https://www.potomacpsychiatry.com/alzheimers-dementia-recode-precode
2. 2https://trademarks.justia.com/878/81/bredesen-87881016.html
3. 3https://trademarks.justia.com/878/81/recode-87881026.html
4. 4https://trademarks.justia.com/878/81/recode-87881026.html
5. 5https://www.apollohealthco.com/solution/recode/
6. 6https://www.potomacpsychiatry.com/alzheimers-dementia-recode-precode
7. 7https://www.potomacpsychiatry.com/alzheimers-dementia-recode-precode
8. 8https://pmc.ncbi.nlm.nih.gov/articles/PMC4221920/
9. 9https://pmc.ncbi.nlm.nih.gov/articles/PMC4221920/
10. 10https://www.apollohealthco.com/solution/recode/
11. 11https://trademarks.justia.com/878/81/bredesen-87881016.html
12. 12https://ttabvue.uspto.gov/ttabvue/v?pnam=AHNP%2C+LLC++
13. 13https://trademarks.justia.com/878/81/recode-87881026.html
14. 14https://www.ftc.gov/legal-library/browse/warning-letters
15. 15https://www.apollohealthco.com/solution/recode/
16. 16https://pmc.ncbi.nlm.nih.gov/articles/PMC9484109/
17. 17https://www.apollohealthco.com/rct-2025/
18. 18https://www.potomacpsychiatry.com/alzheimers-dementia-recode-precode
19. 19https://pmc.ncbi.nlm.nih.gov/articles/PMC4221920/
20. 20https://pmc.ncbi.nlm.nih.gov/articles/PMC7377549/
21. 21https://hal.science/hal-03114575v1/document
22. 22https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.12298
23. 23https://www.apollohealthco.com/to-our-critics/
24. 24https://www.apollohealthco.com/recode-training/
25. 25https://www.apollohealthco.com/recode-training/
26. 26https://app.apollohealthco.com/practitioner-pricing/1373
27. 27https://lakeshorewoodseniors.com/michigans-only-residential-alzheimers-reversal-program/
28. 28https://recodereport.zendesk.com/hc/en-us/articles/360049111451-FAQs-ReCODE-and-PreCODE-Frequently-Asked-Questions
29. 29https://pmc.ncbi.nlm.nih.gov/articles/PMC7377549/
30. 30https://pmc.ncbi.nlm.nih.gov/articles/PMC9484109/
31. 31https://recodesupport.com/terms-conditions/
32. 32https://pubmed.ncbi.nlm.nih.gov/34377527/
33. 33https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?NCAId=240&NcaName=Intensive+Cardiac+Rehabilitation+%28ICR%29+Program+-+Dr.+Ornish&proposed=N
34. 34https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=239
35. 35https://www.survivingmold.com/shoemaker-protocol/list-of-certified-practitioners
36. 36https://pmc.ncbi.nlm.nih.gov/articles/PMC11623837/
37. 37https://pmc.ncbi.nlm.nih.gov/articles/PMC8058406/
38. 38https://pubmed.ncbi.nlm.nih.gov/35458137/
39. 39https://www.cancer.gov/about-cancer/treatment/cam/hp/gonzalez-pdq
40. 40https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen
41. 41https://www.cancer.gov/publications/dictionaries/cancer-terms/def/r-chop
42. 42https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq
43. 43https://tbksp.who.int/en/node/3033
44. 44https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-name-abbreviations
45. 45https://www.uspto.gov/trademarks/basics/strong-trademarks
46. 46https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/bictegravir
47. 47https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox-regimen